Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2024 / May / The CorNeat EverPatch: Superior Alternative to Tissue Grafts
Anterior Segment Cornea Glaucoma Neuro-ophthalmology Pediatric Sponsored

The CorNeat EverPatch: Superior Alternative to Tissue Grafts

First non-degradable bio-integrating device targeting glaucoma tube exposure complications that is tailored for surgeons

Sponsored By CorNeat Vision 5/2/2024 4 min read

Share

The use of an autologous sclera patch graft in human ocular surgery (by Swedish ophthalmologist Sven Larsson) goes back to the mid-1940s; at the same time, R. Townley Paton founded the first eye bank in New York. Preserved human sclera from eye bank donor eyes would come to replace the use of autologous sclera, but back then transplant surgeries had to take place no more than 48 hours after the death of the donor.

Advancements in techniques to preserve ocular tissues over the following decades meant that sclera grafts could be stored for much longer, and scleral reinforcement has become the gold standard as a safety measure in glaucoma drainage device (GDD) surgeries. The use of human tissue in these surgeries, however, has been beset by disadvantages; for example, it is degraded by the body’s inflammatory cells, and there is a limited amount of graft material available. But thanks to the CorNeat EverPatch, these challenges are now surmountable.

As the first alternative to tissue that is synthetic, non-degradable, and sterile, the CorNeat EverPatch remains in the tissue following GDD surgery, and conceals the glaucoma tube shunt for the patient’s life. “The non-degradability of this medical device will have a dramatic impact on the rate of late complications,” says Dr. Gilad Litvin, CorNeat Vision’s Co-Founder and Chief Medical Officer. “And as it is not harvested from cadaveric origin, it is safer, reducing the risk of infection, specifically disease transmission.”

The design and the features of the CorNeat EverPatch were optimized to address the surgeon’s needs, simplifying the procedure. Where current tissue patches have a thickness of 400-500 μm to allow for protection until native scar tissue forms to conceal the tube, the nondegradable EverPatch is much thinner – just 100 μm – which reduces tension on the surgical wound and makes closing it easier for the surgeon. This “durability, flexibility, and resistance to cheese wiring allows easy and accurate manipulation and suturing,” explains Almog Aley-Raz, CorNeat Vision’s CEO and VP R&D.

The EverPatch is based on the EverMatrix™, the company’s disruptive platform material technology. The EverMatrix™ is biocompatible, nondegradable biomimetic material that imitates the micro-structure of the human Extracellular Matrix (ECM) – the collagen mesh providing the structural and biochemical support to surrounding cells. It can be seen as a natural habitat for human fibroblasts, which play a critical role in wound healing and constitute the most common connective tissue cells. Invivo studies have shown the abundant presence of fibroblasts and collagen fibrils within the EverMatrix™ several weeks following its implantation with no adverse immune system response. In addition to the CorNeat EverPatch, the company develops two additional disruptive implants based on its platform technology, the CorNeat KPro – an artificial cornea intended to restore sight in corneally blind individuals – and the CorNeat eShunt – the first shunt that drains in the intraconal space, prolonging efficacy.

Supported by this innovative technology, the CorNeat EverPatch looks set to revolutionize ophthalmic surgery, allowing for scleral implantation in regions where access to donor tissue is scarce, offering ease of handling and manipulation, and eliminating the risk of tube exposure and disease transmission. Since it was soft launched in the US in December 2023, the CorNeat EverPatch has been implanted in dozens of leading ophthalmic centers, gaining excellent feedback from physicians.

www.corneat.com

The CorNeat EverPatch is available for evaluation and sales in the US and other countries relying on FDA regulation

About the Author(s)

Julian Upton

Julian Upton is Group Editor of The Ophthalmologist and The New Optometrist. With 20+ years' experience of the magazine industry, he has covered many facets of science and healthcare.

More Articles by Julian Upton

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: